On June 10, 2016 Cantargia AB reported that the patent application, with application number 13/979,475 that has now received a Notice of Allowance from the USPTO refers to a method for using IL1RAP as target molecule for treatment of solid tumours (Press release, Cantargia, JUN 10, 2016, View Source [SID:1234513204]). The patent covers treatment of several different forms of solid tumours, including breast cancer, colorectal cancer, lung cancer and malignant melanoma. The issuance of a Notice of Allowance indicates that the USPTO intends to approve the company’s patent application. Certain administrative steps remain before the patent is formally granted.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Cantargia has passed yet another very important milestone in the development of our CAN04 product candidate", Göran Forsberg, CEO of Cantargia AB, says. "Once the patent has been formally approved in the US we will have protection in the area of solid tumours in the three largest markets, USA, Europe and Japan."